Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPD NASDAQ:INVA NASDAQ:KNSA NASDAQ:MGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPDAntibe Therapeutics$0.22$2.64▼$3.50$1.21B0.5729,710 shsN/AINVAInnoviva$19.19-3.5%$19.66$16.67▼$22.00$1.21B0.47647,259 shs1.59 million shsKNSAKiniksa Pharmaceuticals International$35.42-1.4%$32.62$17.82▼$37.34$2.62B0.2386,927 shs489,203 shsMGNXMacroGenics$1.62-6.4%$1.63$0.99▼$5.10$102.39M1.631.03 million shs923,220 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%INVAInnoviva0.00%-0.93%-3.91%-8.62%-1.79%KNSAKiniksa Pharmaceuticals International0.00%-4.53%+5.48%+24.54%+40.17%MGNXMacroGenics0.00%+1.89%+12.50%+23.66%-50.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPDAntibe Therapeutics$0.22$2.64▼$3.50$1.21B0.5729,710 shsN/AINVAInnoviva$19.19-3.5%$19.66$16.67▼$22.00$1.21B0.47647,259 shs1.59 million shsKNSAKiniksa Pharmaceuticals International$35.42-1.4%$32.62$17.82▼$37.34$2.62B0.2386,927 shs489,203 shsMGNXMacroGenics$1.62-6.4%$1.63$0.99▼$5.10$102.39M1.631.03 million shs923,220 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPDAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%INVAInnoviva0.00%-0.93%-3.91%-8.62%-1.79%KNSAKiniksa Pharmaceuticals International0.00%-4.53%+5.48%+24.54%+40.17%MGNXMacroGenics0.00%+1.89%+12.50%+23.66%-50.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPDAntibe Therapeutics 0.00N/AN/AN/AINVAInnoviva 3.00Buy$42.75122.77% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1716.22% UpsideMGNXMacroGenics 2.50Moderate Buy$3.60122.22% UpsideCurrent Analyst Ratings BreakdownLatest INVA, KNSA, MGNX, and ATBPD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/17/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.009/16/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025MGNXMacroGenicsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $5.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $54.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.007/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $42.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPDAntibe Therapeutics$7.51M0.00N/AN/A$0.10 per share0.00INVAInnoviva$358.71M3.37$3.43 per share5.60$11.03 per share1.74KNSAKiniksa Pharmaceuticals International$423.24M6.20N/AN/A$6.60 per share5.37MGNXMacroGenics$163.87M0.62N/AN/A$1.85 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPDAntibe Therapeutics-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/AINVAInnoviva$23.39M$0.3161.9112.38N/A10.44%18.67%9.92%11/5/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04885.72141.68N/A0.90%1.05%0.80%11/4/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.57N/AN/AN/A-21.99%-40.24%-14.62%11/4/2025 (Estimated)Latest INVA, KNSA, MGNX, and ATBPD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGNXMacroGenics-$0.59-$0.57+$0.02-$0.57$28.06 million$22.24 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATBPDAntibe TherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPDAntibe TherapeuticsN/A5.975.42INVAInnoviva0.362.642.44KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16MGNXMacroGenicsN/A5.265.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPDAntibe TherapeuticsN/AINVAInnoviva99.12%KNSAKiniksa Pharmaceuticals International53.95%MGNXMacroGenics96.89%Insider OwnershipCompanyInsider OwnershipATBPDAntibe TherapeuticsN/AINVAInnoviva2.25%KNSAKiniksa Pharmaceuticals International53.48%MGNXMacroGenics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPDAntibe Therapeutics47387.00 millionN/ANot OptionableINVAInnoviva10063.02 million61.60 millionOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableMGNXMacroGenics43063.21 million54.99 millionOptionableINVA, KNSA, MGNX, and ATBPD HeadlinesRecent News About These CompaniesMacroGenics (NASDAQ:MGNX) Raised to "Strong-Buy" at BarclaysSeptember 19 at 6:47 AM | marketbeat.comBarclays Reaffirms "Overweight" Rating for MacroGenics (NASDAQ:MGNX)September 18 at 8:14 AM | marketbeat.comMacroGenics (NASDAQ:MGNX) Earns Overweight Rating from Analysts at BarclaysSeptember 18 at 3:11 AM | americanbankingnews.comAcadian Asset Management LLC Boosts Stake in MacroGenics, Inc. $MGNXSeptember 17, 2025 | marketbeat.comMacroGenics initiated with an Overweight at BarclaysSeptember 17, 2025 | msn.comMacroGenics assumed with an Overweight at BarclaysSeptember 17, 2025 | msn.comBrokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $3.60September 15, 2025 | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.com198,470 Shares in MacroGenics, Inc. $MGNX Acquired by Nuveen LLCSeptember 8, 2025 | marketbeat.comMacroGenics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comMacroGenics (NASDAQ:MGNX) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?August 28, 2025 | marketbeat.comWilliam Heiden Bought 909% More Shares In MacroGenicsAugust 23, 2025 | finance.yahoo.comWilliam Heiden Bought 909% More Shares In MacroGenicsAugust 23, 2025 | finance.yahoo.comStifel Nicolaus Keeps Their Hold Rating on MacroGenics (MGNX)August 23, 2025 | theglobeandmail.comMacroGenics (NASDAQ:MGNX) Director William Heiden Acquires 49,500 SharesAugust 22, 2025 | insidertrades.comCitizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)August 17, 2025 | theglobeandmail.comMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic PrioritiesAugust 16, 2025 | uk.finance.yahoo.comMacroGenics Revenue Doubles in Q2August 16, 2025 | theglobeandmail.comMacroGenics price target lowered to $5 from $8 at LeerinkAugust 16, 2025 | msn.comMacroGenics Inc. Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comMacroGenics reports Q2 EPS (57c), consensus (38c)August 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINVA, KNSA, MGNX, and ATBPD Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPDAntibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Innoviva NASDAQ:INVA$19.19 -0.70 (-3.52%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$19.07 -0.13 (-0.65%) As of 09/19/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$35.42 -0.50 (-1.39%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$35.54 +0.13 (+0.35%) As of 09/19/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.MacroGenics NASDAQ:MGNX$1.62 -0.11 (-6.36%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.65 +0.03 (+1.79%) As of 09/19/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
